At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 243 enrolled

Drug / intervention

Misoprostoldrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02680314

NCT02680314Phase 2Completed

Compare CT.gov

Is More Than One Dose of Misoprostol Needed to Expedite Vaginal Delivery in a Patient With an Unripe Cervix?

Montefiore Medical Center·interventional·Posted Feb 11, 2016·Updated Sep 14, 2022

In Brief

A Phase 2 clinical trial evaluating Misoprostol for Labor; Forced or Induced, Affecting Fetus or Newborn. Completed, enrolled 243 participants.

Detailed Summary

The goal of this study is to determine whether inducing labor with just one dose of misoprostol, followed by treatment with oxytocin, will still be effective enough to increase the chances of having a successful vaginal delivery as compared to using more than one dose of misoprostol, followed by treatment with oxytocin.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsLabor; Forced or Induced, Affecting Fetus or Newborn

Countries--

Collaborators--

Timeline

Phase 2CompletedFinished

20162017201820192020202120222023202420252026

Enrollment StartFeb 2016

First PostedFeb 2016

Primary CompletionMay 2017

Study CompletionJun 2021

TodayJul 2026

First PostedFeb 11, 2016

Enrollment StartFeb 1, 2016

Primary CompletionMay 17, 2017

Study CompletionJun 16, 2021

TodayJul 2, 2026

Enrollment to primary: 1.3 yearsPosted 10.4 years ago

Interventions

Misoprostoldrug

Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.